A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP

By sjmartinez • November 29, 2022

Yu Y, Bigos KL, Marzinke MA, Landovitz RJ, McCauley M, Ford S, Hendrix CW, Bies RR, Weld ED; HPTN 077 Study Team. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP. Br J Clin Pharmacol. 2022 Oct;88(10):4623-4632. doi: 10.1111/bcp.15477. Epub 2022 Aug 14. PMID: 35949044.

Tags: antiretrovirals, HIV/AIDS, Infectious Diseases, infectious diseases, pharmacometrics, Publications

Related Posts

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative

Wohl DA, Adam SJ, Gibbs KW, Moskowitz AL, Ortel TL, Singh U, Jilg N, Evering TH, Fischer WA 2nd, Taiwo BO, Daar ES, Lindsell CJ,[...]